16/120
0.7 / 5 stars
All 120 Win/Lose results shown below
SER Roast Me summary
Serina Therapeutics, Inc. (SER). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
Trailing 1 year (4 quarters): 2 wins, 10 lossesLast fetched: 24 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseSER / S&P 0.00% / 15.20% |
LoseSER / S&P SER unavailable / 15.00% |
LoseSER / S&P SER unavailable / 50.40% |
| 2026-Q11/3 |
WinSER / S&P 1.41% / -4.33% |
LoseSER / S&P SER unavailable / 11.30% |
LoseSER / S&P SER unavailable / 27.70% |
| 2025-Q41/3 |
LoseSER / S&P -64.31% / 2.65% |
WinSER / S&P 132.14% / 9.00% |
LoseSER / S&P SER unavailable / 13.40% |
| 2025-Q30/3 |
LoseSER / S&P -12.99% / 8.12% |
LoseSER / S&P -96.33% / 4.61% |
LoseSER / S&P SER unavailable / 13.45% |
| 2025-Q20/3 |
LoseSER / S&P 8.64% / 10.94% |
LoseSER / S&P -95.90% / 4.83% |
LoseSER / S&P SER unavailable / 10.63% |
| 2025-Q11/3 |
WinSER / S&P 13.17% / -4.27% |
LoseSER / S&P -98.37% / 4.98% |
LoseSER / S&P SER unavailable / 10.57% |
| 2024-Q40/3 |
LoseSER / S&P -25.11% / 2.41% |
LoseSER / S&P -98.22% / 5.25% |
LoseSER / S&P -306.85% / 6.15% |
| 2024-Q31/3 |
LoseSER / S&P -30.17% / 5.89% |
WinSER / S&P 4166.22% / 5.89% |
LoseSER / S&P SER unavailable / 6.11% |
| 2024-Q21/3 |
LoseSER / S&P -28.83% / 4.28% |
WinSER / S&P 5774.07% / 5.38% |
LoseSER / S&P SER unavailable / 5.12% |
| 2024-Q11/3 |
LoseSER / S&P -2.11% / 10.56% |
WinSER / S&P 5201.69% / 5.71% |
LoseSER / S&P SER unavailable / 5.59% |
| 2023-Q41/3 |
LoseSER / S&P -43.38% / 11.69% |
WinSER / S&P 9173.53% / 6.81% |
LoseSER / S&P SER unavailable / 7.78% |
| 2023-Q31/3 |
LoseSER / S&P -23.85% / -3.27% |
WinSER / S&P 39.62% / 7.52% |
LoseSER / S&P SER unavailable / -5.03% |
| 2023-Q21/3 |
WinSER / S&P 34.69% / 8.74% |
LoseSER / S&P -20.59% / 9.50% |
LoseSER / S&P SER unavailable / -8.57% |
| 2023-Q11/3 |
WinSER / S&P 20.11% / 7.50% |
LoseSER / S&P -36.56% / 10.77% |
LoseSER / S&P SER unavailable / -15.69% |
| 2022-Q40/3 |
LoseSER / S&P -1.78% / 7.56% |
LoseSER / S&P -76.39% / 11.88% |
LoseSER / S&P SER unavailable / -17.99% |
| 2022-Q31/3 |
WinSER / S&P -2.43% / -4.88% |
LoseSER / S&P -80.73% / 13.47% |
LoseSER / S&P SER unavailable / -1.41% |
| 2022-Q20/3 |
LoseSER / S&P -32.55% / -16.10% |
LoseSER / S&P -78.75% / 13.71% |
LoseSER / S&P SER unavailable / 11.04% |
| 2022-Q10/3 |
LoseSER / S&P -21.65% / -4.60% |
LoseSER / S&P -71.65% / 15.97% |
LoseSER / S&P SER unavailable / 42.23% |
| 2021-Q41/3 |
WinSER / S&P 15.96% / 11.03% |
LoseSER / S&P -60.11% / 15.00% |
LoseSER / S&P SER unavailable / 96.40% |
| 2021-Q30/3 |
LoseSER / S&P -39.35% / 0.58% |
LoseSER / S&P -63.43% / 10.77% |
LoseSER / S&P SER unavailable / 69.42% |
| 2021-Q20/3 |
LoseSER / S&P -4.32% / 8.55% |
LoseSER / S&P -70.75% / 6.58% |
LoseSER / S&P SER unavailable / 51.81% |
| 2021-Q11/3 |
WinSER / S&P 6.58% / 6.17% |
LoseSER / S&P -77.05% / -1.06% |
LoseSER / S&P SER unavailable / 7.39% |
| 2020-Q41/3 |
WinSER / S&P 87.65% / 12.15% |
LoseSER / S&P -79.11% / -3.72% |
LoseSER / S&P SER unavailable / -33.42% |
| 2020-Q30/3 |
LoseSER / S&P -14.47% / 8.93% |
LoseSER / S&P -49.60% / -2.04% |
LoseSER / S&P SER unavailable / -27.10% |
| 2020-Q20/3 |
LoseSER / S&P 1.83% / 20.54% |
LoseSER / S&P -25.12% / -0.46% |
LoseSER / S&P SER unavailable / -27.11% |
| 2020-Q10/3 |
LoseSER / S&P -48.90% / -19.60% |
LoseSER / S&P -7.51% / 3.47% |
LoseSER / S&P SER unavailable / -14.75% |
| 2019-Q41/3 |
LoseSER / S&P -7.14% / 9.07% |
WinSER / S&P 23.78% / 5.36% |
LoseSER / S&P SER unavailable / 2.99% |
| 2019-Q30/3 |
LoseSER / S&P -46.59% / 1.70% |
LoseSER / S&P SER unavailable / 5.02% |
LoseSER / S&P SER unavailable / 0.21% |
| 2019-Q20/3 |
LoseSER / S&P -9.38% / 4.30% |
LoseSER / S&P SER unavailable / 6.64% |
LoseSER / S&P SER unavailable / 8.65% |
| 2019-Q11/3 |
WinSER / S&P 35.45% / 13.65% |
LoseSER / S&P SER unavailable / 8.12% |
LoseSER / S&P SER unavailable / 14.29% |
| 2018-Q40/3 |
LoseSER / S&P SER unavailable / -13.52% |
LoseSER / S&P -0.57% / 9.05% |
LoseSER / S&P SER unavailable / 18.23% |
| 2018-Q30/3 |
LoseSER / S&P SER unavailable / 7.71% |
LoseSER / S&P SER unavailable / 10.21% |
LoseSER / S&P SER unavailable / 19.06% |
| 2018-Q20/3 |
LoseSER / S&P SER unavailable / 3.43% |
LoseSER / S&P SER unavailable / 9.03% |
LoseSER / S&P SER unavailable / 14.46% |
| 2018-Q10/3 |
LoseSER / S&P SER unavailable / -0.76% |
LoseSER / S&P SER unavailable / 7.68% |
LoseSER / S&P SER unavailable / 12.46% |
| 2017-Q40/3 |
LoseSER / S&P SER unavailable / 6.64% |
LoseSER / S&P SER unavailable / 7.03% |
LoseSER / S&P SER unavailable / 13.82% |
| 2017-Q30/3 |
LoseSER / S&P SER unavailable / 4.48% |
LoseSER / S&P SER unavailable / 5.68% |
LoseSER / S&P SER unavailable / 17.57% |
| 2017-Q20/3 |
LoseSER / S&P SER unavailable / 3.09% |
LoseSER / S&P SER unavailable / 4.83% |
LoseSER / S&P SER unavailable / 17.74% |
| 2017-Q10/3 |
LoseSER / S&P SER unavailable / 6.07% |
LoseSER / S&P SER unavailable / 3.67% |
LoseSER / S&P SER unavailable / 13.32% |
| 2016-Q40/3 |
LoseSER / S&P SER unavailable / 3.82% |
LoseSER / S&P SER unavailable / 2.09% |
LoseSER / S&P SER unavailable / 7.05% |
| 2016-Q30/3 |
LoseSER / S&P SER unavailable / 3.85% |
LoseSER / S&P SER unavailable / 0.20% |
LoseSER / S&P SER unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | SER total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -55.20% | 20.78% |
| Annualized return | -55.20% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | SER total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -93.58% | 83.14% |
| Annualized return | -42.26% | 12.86% |
10Y · 2018-11-29 to 2026-08-28
| Metric | SER total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -97.54% | 319.30% |
| Annualized return | -30.95% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-24.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |